ShareThis Page
Business Headlines

Generic drugmaker to sell alternative to EpiPen injectors

| Thursday, Dec. 6, 2018, 8:30 p.m.
Amid persistent shortages of EpiPens and other emergency autoinjectors that treat life-threatening allergic reactions, generic drugmaker Sandoz says that early next year it will launch a slightly cheaper rival in the United States. Sandoz said Thursday, Dec. 6, 2018, that it plans to sell a pair of its generic autoinjectors for $250 without insurance.
Amid persistent shortages of EpiPens and other emergency autoinjectors that treat life-threatening allergic reactions, generic drugmaker Sandoz says that early next year it will launch a slightly cheaper rival in the United States. Sandoz said Thursday, Dec. 6, 2018, that it plans to sell a pair of its generic autoinjectors for $250 without insurance.

TRENTON, N.J. — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the United States early next year.

The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since the spring because of production problems.

Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance.

Two generic versions of EpiPen are sold in the United States for $300 a pair, including one from EpiPen seller Mylan. The company started selling its own generic after it was blasted for repeated hikes that pushed up its list price from $94 to $608 for a pair of brand-name EpiPens.

What people pay varies, though, depending on insurance, discounts and the pharmacy.

Mylan’s injectors are made by a subsidiary of Pfizer, which is upgrading factories to fix quality problems. That resulted in production slowdowns. Pfizer said Thursday it’s shipping some injectors and expects to ship more in the coming months.

The shortages triggered temporary shortages of other similar products, including Auvi-Q. As a result, U.S. regulators let some manufacturers extend expiration dates.

Sandoz, part of Novartis AG, will sell syringes with an adult dose made by Adamis Pharmaceuticals Corp. A children’s version will follow.

Israel’s Teva Pharmaceutical Industries began selling limited quantities of its new generic EpiPen in the United States last week.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me